Mona Ashiya - 24 Mar 2025 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 Mar 2025, 19:08:01 UTC
Prior SEC filing
21 Mar 2025
Next SEC filing
13 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mona Ashiya

Key filing fact

Mona Ashiya filed Form 4 for Disc Medicine, Inc. (IRON) on 26 Mar 2025.

Key facts

  • This page summarizes Mona Ashiya's Form 4 filing for Disc Medicine, Inc. (IRON).
  • 3 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 26 Mar 2025, 19:08.

Change

  • Previous filing in this sequence was filed on 21 Mar 2025.
  • Current net transaction value: -$310,483.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRON transaction

Common Stock

Sale

Transaction value
$105,839
Shares
-1,956
Change %
-0.4%
Price
$54.11
Shares after
482,308
Date
24 Mar 2025
Ownership
See Footnotes
Footnotes
F1, F4
IRON transaction

Common Stock

Sale

Transaction value
$163,737
Shares
-3,026
Change %
-0.4%
Price
$54.11
Shares after
746,171
Date
24 Mar 2025
Ownership
See Footnotes
Footnotes
F2, F4
IRON transaction

Common Stock

Sale

Transaction value
$40,907
Shares
-756
Change %
-0.4%
Price
$54.11
Shares after
186,541
Date
24 Mar 2025
Ownership
See Footnotes
Footnotes
F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

Footnote F2

These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

Footnote F3

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

Footnote F4

Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .